Baum RP - Search Results

Year	Number of Results
1974	1
1985	2
1986	3
1987	5
1988	6
1989	8
1990	8
1991	5
1992	1
1993	6
1994	9
1995	8
1996	3
1997	11
1998	14
1999	7
2000	2
2001	3
2002	1
2003	10
2004	4
2005	1
2006	1
2007	7
2008	2
2009	5
2010	16
2011	14
2012	18
2013	15
2014	16
2015	19
2016	19
2017	14
2018	16
2019	17
2020	17
2021	13
2022	10
2023	7
2024	11
2025	17
2026	8

1

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using ¹⁷⁷Lu-, ⁹⁰Y-, and ²²⁵Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Baum RP, Zhao T, Jakobsson V, Greifenstein L, Eismant A, Ghai K, Mishra A, Klega A, Landvogt C, Mueller C, Benz-Zils D, Klein O, Jaeschke B, Perrone E, Zhang J. Baum RP, et al. J Nucl Med. 2026 Jun 1;67(6):910-920. doi: 10.2967/jnumed.125.271129. J Nucl Med. 2026. PMID: 42225357

2

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

Perrone E, Greifenstein L, Ghai K, Wirtz RM, Baum RP. Perrone E, et al. Among authors: baum rp. Clin Nucl Med. 2026 May 1;51(5):e346-e347. doi: 10.1097/RLU.0000000000006222. Epub 2025 Nov 26. Clin Nucl Med. 2026. PMID: 41921940

3

Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.

Greifenstein L, Martin M, Stephan S, Eismant A, Kramer CS, Landvogt C, Mueller C, Rösch F, Baum RP. Greifenstein L, et al. Among authors: baum rp. Pharmaceuticals (Basel). 2026 Jan 19;19(1):172. doi: 10.3390/ph19010172. Pharmaceuticals (Basel). 2026. PMID: 41599769 Free PMC article.

4

Current status of FAP therapy in solid tumors.

Siegmund SC, Novruzov E, Mamlins E, Mori Y, Otto S, Canis M, Watabe T, Baum RP, Werner RA, Giesel FL. Siegmund SC, et al. Among authors: baum rp. Semin Nucl Med. 2026 Jan;56(1):40-52. doi: 10.1053/j.semnuclmed.2025.11.022. Epub 2025 Dec 26. Semin Nucl Med. 2026. PMID: 41455672 Free article. Review.

5

Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years.

Zhang J, Mensel B, Baum RP. Zhang J, et al. Among authors: baum rp. Theranostics. 2026 Jan 1;16(4):1658-1670. doi: 10.7150/thno.112012. eCollection 2026. Theranostics. 2026. PMID: 41356201 Free PMC article.

6

Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.

Santo G, Rodrigues M, Paez D, Morozova O, Kabasakal L, Kairemo K, Grana CM, Baum RP, di Santo G, Virgolini IJ. Santo G, et al. Among authors: baum rp. Theranostics. 2026 Jan 1;16(3):1227-1237. doi: 10.7150/thno.123273. eCollection 2026. Theranostics. 2026. PMID: 41355961 Free PMC article.

7

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

Perrone E, Shaheen S, Kunz PL, Henri HC, Baum RP. Perrone E, et al. Among authors: baum rp. Clin Nucl Med. 2026 Jul 1;51(7):e484-e486. doi: 10.1097/RLU.0000000000006201. Epub 2025 Oct 29. Clin Nucl Med. 2026. PMID: 41308086

8

Systematic review and meta-analysis of the efficacy and safety of [¹⁷⁷Lu]Lu-edotreotide ([¹⁷⁷Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.

Baum RP, Fricke JG, Ruhwedel T, Amthauer H, Azorin-Vega EP, Hörsch D, Laudicella R, Maheshwari V, Walter MA, Polack BD, Spiegl SF, Nicolas GP. Baum RP, et al. J Neuroendocrinol. 2026 Jan;38(1):e70103. doi: 10.1111/jne.70103. Epub 2025 Nov 8. J Neuroendocrinol. 2026. PMID: 41204752 Free PMC article.

9

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Perrone E, Calcagni ML, Leccisotti L, Moretti R, Ghai K, Eismant A, Parkar T, Greifenstein L, Baum RP. Perrone E, et al. Among authors: baum rp. Cancers (Basel). 2025 Sep 19;17(18):3070. doi: 10.3390/cancers17183070. Cancers (Basel). 2025. PMID: 41008911 Free PMC article.

10

The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.

Singh A, Sanduleanu S, Kulkarni HR, Langbein T, Lambin P, Baum RP. Singh A, et al. Among authors: baum rp. Front Endocrinol (Lausanne). 2025 Jun 24;16:1514792. doi: 10.3389/fendo.2025.1514792. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40630096 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

352 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Results by year